FDA 503b; Compounding; Glp-1s; Health
-
FDA Moves to Permanently Close the Door on Compounded GLP-1s (semaglutide, tirzepatide, and liraglutide)
The agency's proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List signals that large-scale compounding of these agents has no regulatory future, and carries immediate implications for pharmacy practice. The FDA has announced that it is proposing to formally...- madman
- Thread
- FDA 503b; Compounding; Glp-1s; Health
- Replies: 2
- Forum: Weight Loss Options
Sponsors
FDA 503b; Compounding; Glp-1s; Health
